Multilayered nanoparticles for personalized medicine: Translation into clinical markets

Handbook of Clinical Nanomedicine: Nanoparticles, Imaging, Therapy and Clinical Applications

Volumn 1, Issue , 2016, Pages 299-318

  Movia, Dania ^a   Poland, Craig ^b   Tran, Lang ^b   Volkov, Yuri ^a,c   Prina Mello, Adriele ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b INSTITUTE OF OCCUPATIONAL MEDICINE   (United Kingdom)

^c TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Engineered nanoparticles; High content screening translational medicine; High throughput screening; Modeling; Multilayered theranostic ENP; Nanomedicine; Personalized medicine; Quantitative nanostructure toxicity relationship; Risk assessment; Structure activity relationship

Indexed keywords

MEDICAL NANOTECHNOLOGY; MODELS; NANOPARTICLES; RISK ASSESSMENT;

ENGINEERED NANOPARTICLES; HIGH THROUGHPUT SCREENING; MULTI-LAYERED; PERSONALIZED MEDICINES; QUANTITATIVE NANOSTRUCTURE-TOXICITY RELATIONSHIP; STRUCTURE ACTIVITY RELATIONSHIPS; TRANSLATIONAL MEDICINE;

DIAGNOSIS;

EID: 85015870128     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814669214     Document Type: Chapter

References (46)

1. Chen, X., Gambhir, S. S., Cheon, J. (2011). Theranostic nanomedicine. Acc. Chem. Res., 44(10), 841-841.
2. Linkov, I., Bates, M. E., Canis, L. J., Seager, T. P., Keisler, J. M. (2011). A decision-directed approach for prioritizing research into the impact of nanomaterials on the environment and human health Nat. Nanotechnol., 6, 784-787.
3. Ebbesen, J., Buajordet, I., Erikssen, J., Brors, O., Hilberg, T., et al. (2001). Drug-related deaths in a department of internal medicine. Arch. Intern. Med., 161(19), 2317-2323.
4. Vizirianakis, I. S. (2011). Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug-delivery outcomes. Nanomedicine, 7(1), 11-17.
5. Vizirianakis, I. S. (2005). Improving pharmacotherapy outcomes by pharmacogenomics: From expectation to reality? Pharmacogenomics, 6(7), 701-711.
6. Yildirimer, L., Thanh, N. T. K., Loizidou, M., Seifalian, A. M. (2011). Toxicological considerations of clinically applicable nanoparticles. Nano Today, 6, 585-607.
7. Chai, C. Global Nanomedicine Market to Reach $130.9 Billion by 2016, Available at: http://www.azonano.com/news.aspx?newsID=24136 (accessed on October 18, 2014).
8. Global Industry Analyst, I. Nanotechnology in Medical Applications:The Global Market, Available at: http://www.bccresearch.com/report/nanotechnology-medical-applications-global-market-hlc069b.html (Accessed on October 18, 2014).
9. Lammers, T., Aime, S., Hennink, W. E., Storm, G., Kiessling, F. (2011). Theranostic nanomedicine. Acc. Chem. Res., 44(10), 1029-1038.
10. Kievit, F. M., Zhang, M. (2011). Surface engineering of iron oxide nanoparticles for target cancer therapy. Acc. Chem. Res., 44(10), 853-862.
11. Yigit, M. V., Moore, A., Medarova, Z. (2012). Magnetic nanoparticles for cancer diagnosis and therapy. Pharm. Res., 29(5), 1180-1188.
12. Ventola, C. L. (2012). The nanomedicine revolution: Part 1: Emerging concepts. P T, 37(9), 512-525.
13. Doane, T. L., Burda, C. (2012). The unique role of nanoparticles in nanomedicine: Imaging, drug delivery and therapy. Chem. Soc. Rev., 41(7), 2885-2911.
14. Eaton, M. A. W. (2011). How do we develop nanopharmaceuticals under open innovation? Nanomed. Nanotechnol. Biol. Med., 7(4), 371-375.
15. The Editors (2012). Join the dialogue. Nat. Nanotechnol., 7(9), 545.
16. Schrurs, F., Lison, D. (2012). Focusing the research efforts. Nat. Nanotechnol., 7(9), 546-548.
17. Hartung, T. (2009). Toxicology for the twenty-first century. Nature, 460(7252), 208-212.
18. Hoffmann, S., Cole, T., Hartung, T. (2005). Skin irritation: Prevalence, variability, and regulatory classification of existing in vivo data from industrial chemicals. Regul. Toxicol. Pharm., 41(3), 159-166.
19. Service, R. F. (2008). Nanotechnology: Can high-speed tests sort out which nanomaterials are safe? Science, 321(5892), 1036-1037.
20. Höfer, T., Gerner, I., Gundert-Remy, U., Liebsch, M., Schulte, A., et al. (2004). Animal testing and alternative approaches for the human health risk assessment under the proposed new European chemicals regulation. Arch. Toxicol., 78(10), 549-564.
21. Stone, V., Johnston, H., Schins, R. P. F. (2009). Development of in vitro systems for nanotoxicology: Methodological considerations. Crit. Rev. Toxicol., 39(7), 613-626.
22. Jones, C. F., Grainger, D. W. (2009). In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev., 61(6), 438-456.
23. Meng, H., Xia, T., George, S., Nel, A. E. (2009). A predictive toxicological paradigm for the safety assessment of nanomaterials. ACS Nano, 3(7), 1620-1627.
24. Nel, A., Xia, T., Madler, L., Li, N. (2006). Toxic potential of materials at the nanolevel. Science, 311(5761), 622-627.
25. Walker, N. J., Bucher, J. R. (2009). A 21st century paradigm for evaluating the health hazards of nanoscale materials? Toxicol. Sci., 110(2), 251-254.
26. Byrne, F., Prina-Mello, A., Whelan, A., Mohamed, B. M., Davies, A., et al. (2009). High content analysis of the biocompatibility of nickel nanowires. J. Magn. Magn. Mater., 321(10), 1341-1345.
27. Rivera Gil, P., Oberdorster, G., Elder, A., Puntes, V., Parak, W. J. (2010). Correlating physico-chemical with toxicological properties of nanoparticles: The present and the future. ACS Nano, 4(10), 5527-5531.
28. Oberdorster, G., Maynard, A., Donaldson, K., Castranova, V., Fitzpatrick, J., et al. (2005). Principles for characterizing the potential human health effects from exposure to nanomaterials: Elements of a screening strategy. Particle Fibre Toxicol., 2(1), 1-8.
29. Nel, A. E., Madler, L., Velegol, D., Xia, T., Hoek, E. M., et al. (2009). Understanding biophysicochemical interactions at the nano-bio interface. Nat. Mater., 8(7), 543-557.
30. Lynch, I., Cedervall, T., Lundqvist, M., Cabaleiro-Lago, C., Linse, S., et al. (2007). The nanoparticle-protein complex as a biological entity:a complex fluids and surface science challenge for the 21st century. Adv. Colloid Interface Sci., 134-35, 167-174.
31. Donaldson, K., Murphy, F. A., Duffin, R., Poland, C. A. (2010). Asbestos, carbon nanotubes and the pleural mesothelium: A review of the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma. Particle Fibre Toxicol., 7(5), 1-7.
32. Weinshilboum, R. (2003). Inheritance and drug response. N. Engl. J. Med., 348(6), 529-537.
33. Advancing Regulatory Science for Public Health, Available at: http://www.fda.gov/ScienceResearch/SpecialTopics/RegulatoryScience/ucm228131.htm (accessed on October 18, 2014).
34. Aitken, R., Stone, V., Hankin, S., Aschberger, K., Baun, A., Christensen, F., Fernandes, T., Hansen, S. F., Hartmann, N. B., Hutchinson, G., et al. (2010). Engineered Nanoparticles: Review of Health and Environmental Safety (ENRHES), Project Final Report, European Commission:Brussels, Belgium, pp. 350-365.
35. Walczyk, D., Bombelli, F. B., Monopoli, M. P., Lynch, I., Dawson, K. A. (2010). What the Cell "sees" in bionanoscience. J. Am. Chem. Soc., 132(16), 5761-5768.
36. Cottens, S., Eaton, M., Fuhr, J., Geary, S., Johnson, D. S., Li G., Raveglia, L., Robertson, G. M., Westwell, A. (2011). Ask the experts: Future of the pharmaceutical industry. Interview by Future Medicinal Chemistry. Future Med. Chem., 3(15), 1863-72.
37. Reich, E. S. (2011). Nano rules fall foul of data gap. Nature, 480, 160-161.
38. Hankin, S., Boraschi, D., Duschl, A., Lehr, C. M., Lichtenbeld, H. (2011). Towards nanotechnology regulation: Publish the unpublishable. Nano Today, 6(3), 228-231.
39. Muller, L., Riediker, M., Wick, P., Mohr, M., Gehr, P., et al. (2010). Oxidative stress and inflammation response after nanoparticle exposure:Differences between human lung cell monocultures and an advanced three-dimensional model of the human epithelial airways. J. R. Soc. Interface, 7, S27-S40.
40. Movia, D., Prina-Mello, A., Bazou, D., Del Canto, E., Volkov, Y., et al. (2011). Screening the cytotoxicity of single-walled carbon nanotubes using novel 3D tissue-mimetic models. ACS Nano, 5(11), 9278-9290.
41. Lynch, I., Salvati, A., Dawson, K. A. (2009). Protein-nanoparticle interactions: What does the cell see? Nat. Nanotechnol., 4(9), 546-547.
42. Romoser, A., Ritter, D., Majitha, R., Meissner, K. E., McShane, M., et al. (2011). Mitigation of quantum dot cytotoxicity by microencapsulation. PloS One, 6(7).
43. Berg, J. M., Romoser, A., Banerjee, N., Zebda, R., Sayes, C. M. (2009). The relationship between pH and zeta potential of similar to 30 nm metal oxide nanoparticle suspensions relevant to in vitro toxicological evaluations. Nanotoxicology, 3(4), 276-283.
44. Sayes, C. M., Warheit, D. B. (2009). Characterization of nanomaterials for toxicity assessment. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 1(6), 660-670.
45. Warheit, D. B., Reed, K. L., Sayes, C. M. (2010). Assessing the role of surface characteristics in nanoparticle-related pulmonary toxicity and inflammation. Int. J. Toxicol., 29(1), 133-134.
46. Fubini, B., Ghiazza, M., Fenoglio, I. (2010). Physico-chemical features of engineered nanoparticles relevant to their toxicity. Nanotoxicology, 4(4), 347-363.